LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

Home・Listă Acțiuni・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Închisă

SectorSănătate

20 -6.19

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

19.92

Maxim

21.33

Indicatori cheie
By Trading Economics
Venit	-29M -11M
Vânzări	-24M 105M
EPS	-0.09
Marjă de profit	-10.717
Angajați	354
EBITDA	-31M -8.5M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+62.43% upside

Dividende
By Dow Jones
Următoarele câștiguri	5 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-281M 2.7B
Deschiderea anterioară	26.19
Închiderea anterioară	20

Sentimentul știrilor

By Acuity

50%

157 / 345 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

12.42 / 14.93 Suport & Rezistență

Arcutis Biotherapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

18 mai 2026, 23:10 UTC

Acțiuni populare

Stocks to Watch: Agilysys, XP

18 mai 2026, 18:44 UTC

Principalele dinamici ale pieței

Claritev Shares Recover After Comments About DOJ

18 mai 2026, 23:55 UTC

Câștiguri

Review & Preview: Earnings' Last Gasp -- Barrons.com

18 mai 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18 mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18 mai 2026, 23:37 UTC

Market Talk

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18 mai 2026, 22:31 UTC

Achiziții, Fuziuni, Preluări

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18 mai 2026, 22:30 UTC

Achiziții, Fuziuni, Preluări

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18 mai 2026, 22:30 UTC

Achiziții, Fuziuni, Preluări

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18 mai 2026, 22:25 UTC

Achiziții, Fuziuni, Preluări

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18 mai 2026, 22:24 UTC

Achiziții, Fuziuni, Preluări

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18 mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18 mai 2026, 20:50 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Financial Services Roundup: Market Talk

18 mai 2026, 20:25 UTC

Câștiguri

Correct: XP 1Q Total Client Assets BRL1.53T

18 mai 2026, 20:23 UTC

Câștiguri

XP 1Q Total Client Assets BRL1.53B

18 mai 2026, 20:19 UTC

Câștiguri

XP 1Q Adj EPS BRL2.49 >XP

18 mai 2026, 20:19 UTC

Câștiguri

XP 1Q Rev BRL4.73B >XP

18 mai 2026, 19:10 UTC

Market Talk

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18 mai 2026, 19:00 UTC

Câștiguri

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18 mai 2026, 18:52 UTC

Market Talk

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18 mai 2026, 18:17 UTC

Market Talk

Achiziții, Fuziuni, Preluări

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18 mai 2026, 17:22 UTC

Market Talk

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18 mai 2026, 16:57 UTC

Achiziții, Fuziuni, Preluări

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18 mai 2026, 16:57 UTC

Market Talk

Global Energy Roundup: Market Talk

18 mai 2026, 16:57 UTC

Market Talk

Commodities Higher as Traders Want Physical Assets -- Market Talk

18 mai 2026, 16:54 UTC

Achiziții, Fuziuni, Preluări

Vinci Doesn't Set Out Financial Details of Deal

18 mai 2026, 16:50 UTC

Achiziții, Fuziuni, Preluări

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18 mai 2026, 16:49 UTC

Achiziții, Fuziuni, Preluări

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18 mai 2026, 16:49 UTC

Achiziții, Fuziuni, Preluări

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18 mai 2026, 16:48 UTC

Achiziții, Fuziuni, Preluări

Vinci Buys Canada's Modern Group of Companies

Comparație

Modificare preț

Arcutis Biotherapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

62.43% sus

Prognoză pe 12 luni

Medie 34.63 USD 62.43%

Maxim 36 USD

Minim 33 USD

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruArcutis Biotherapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

8 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 8 analiști care au acordat evaluări ale acțiunilor Arcutis Biotherapeutics Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

12.42 / 14.93Suport & Rezistență

Recent bearish events outweigh bullish events.

There is one bullish event.

Sentiment

By Acuity

157 / 345 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.